We will be attending #ESMO24 in Barcelona, Spain on September 13-17th. We look forward to connecting with the world's leading oncology professionals and sharing how our portfolio of kitted NGS solutions are driving actionable, accessible results to everyone, everywhere. Stop by Booth 443 and meet our team.
Pillar Biosciences Incorporated
Biotechnology
Natick, Massachusetts 7,373 followers
Localizing NGS testing to empower decisions across the entire healthcare journey for everyone, everywhere
About us
As the leader in Decision Medicine™, Pillar’s technology platform drives significantly more efficient and accessible NGS testing with industry-leading accuracy and sensitivity. Pillar’s extensive portfolio applies across the entire patient journey, from profiling to therapy selection and monitoring, generating actionable insights to get patients on the right therapy faster In conjunction with the SLIMamp assay technology, Pillar Biosciences has an informatics pipeline called the Pillar Variant Analysis Toolkit (PiVAT) that is not only highly accurate, enabling somatic variant calls down to 1% allele frequency without use of Unique Identifiers (UIDs), but also fast and efficient, returning valuable sample data quickly. For higher-sensitivity applications such as cell-free DNA analyses, Pillar Biosciences has developed a dedicated assay technology for cell-free DNA that uses UID methodology, to work with the PiVAT pipeline to drive sensitivity down to 0.1%-0.2%.
- Website
-
https://pillarbiosci.com
External link for Pillar Biosciences Incorporated
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Natick, Massachusetts
- Type
- Privately Held
- Founded
- 2014
- Specialties
- NGS, Target Enrichment, Molecular Pathology, cell-free DNA analysis, Liquid Biopsy, Multiplex PCR, Personalized Medicine, and Precision Medicine
Locations
-
Primary
9 Strathmore Rd
Natick, Massachusetts 01760, US
Employees at Pillar Biosciences Incorporated
-
Randy Pritchard
CEO and Board Member at Pillar Biosciences Incorporated
-
Jamie Lim
Associate Director Project Management at Pillar Bio
-
Christopher J. Jowett
Inspirational Sales & Marketing Leader l Go-to-Market Strategy Development & Execution l Global Product Launch l Molecular Diagnostics & Life…
-
Gang Song
Chairman of the Board at Pillar Biosciences Incorporated
Updates
-
In just one week, September 7-11, the Pillar Biosciences Incorporated team will be at the 36th European Congress of Pathology in Florence, Italy #ECP2024. Stop by Booth #114 to meet the team and discover how our portfolio of rapid, kitted NGS panels are driving actionable, accessible results to everyone, everywhere through localized testing.
-
Pillar Biosciences Incorporated launches oncoReveal Nexus at one of the Nation’s most renowned cancer centers. Read more: https://lnkd.in/eujVi5i4
-
Join us in Barcelona, Spain for #ESMO24, September 13th - 17th. We are thrilled to join the largest global conference for oncology (ESMO - European Society for Medical Oncology) and share how our full portfolio of (RUO) oncoReveal kitted NGS solutions are driving actionable, accessible results to everyone, everywhere. Visit us at Booth #443 to learn more.
-
📣 Have you registered for our August 27th webinar hosted by GenomeWeb yet? Save your seat today as John Longshore, Ph.D., FACMG and Dr. Pantelis Constantoulakis discuss, "Accelerating Access to Liquid Biopsy Testing with Kitted NGS Solutions." In this webinar, we will review: - The importance of liquid biopsy testing in guiding access to precision therapies and clinical trials. - The challenges faced by global pharmaceutical companies regarding patient access to liquid biopsy and new strategies to improve access. - A laboratory evaluation of the performance, workflow, and cost of Pillar Biosciences' suite of kitted liquid biopsy-based assays. Register today to join the discussion: https://lnkd.in/eQ2BvzKt
-
Pillar Biosciences' FDA Approved Solid Tumor NGS Kit oncoReveal CDx Launched at Molecular Pathology Laboratory Network, Inc. (MPLN) as the 1st National molecular reference laboratory to verify and launch oncoReveal CDx. Read the full announcement here: https://lnkd.in/eDWVd2nx
-
Liquid biopsy testing has expanded beyond large centralized CLIA reference labs. Today, local and regional laboratories are expanding the global reach of liquid biopsy testing by leveraging in-house NGS platforms. With the use of these platforms, patients can access local testing more readily, enabling more timely, efficient, and cost-effective care. 📅 Join us on August 27th as John Longshore, Ph.D., FACMG and Dr. PANTELIS CONSTANTOULAKIS discuss the challenges and new strategies that are helping to improve patient access to liquid biopsy. Register today: https://lnkd.in/eQ2BvzKt
-
Pillar Biosciences Incorporated is dedicated to driving global access to kitted NGS testing.
-
Thrilled to have Jean-Claude Gerard join the Pillar Biosciences Incorporated Team as Head of EMEA. Great things coming!!